Research Analysts Set Expectations for Clorox Q1 Earnings

The Clorox Company (NYSE:CLX) – Equities research analysts at Zacks Research reduced their Q1 2027 EPS estimates for shares of Clorox in a research report issued on Tuesday, February 17th. Zacks Research analyst Team now anticipates that the company will post earnings of $1.31 per share for the quarter, down from their prior estimate of $1.32. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Clorox’s current full-year earnings is $7.15 per share. Zacks Research also issued estimates for Clorox’s Q4 2027 earnings at $2.30 EPS, Q1 2028 earnings at $1.37 EPS and FY2028 earnings at $7.23 EPS.

Clorox (NYSE:CLX) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $1.39 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.04). Clorox had a net margin of 11.17% and a return on equity of 383.01%. The firm had revenue of $1.67 billion for the quarter, compared to analysts’ expectations of $1.64 billion. During the same quarter in the previous year, the business earned $1.55 EPS. The company’s revenue for the quarter was down .8% on a year-over-year basis.

A number of other equities research analysts also recently issued reports on CLX. Royal Bank Of Canada set a $132.00 price target on shares of Clorox in a research note on Wednesday, February 4th. Weiss Ratings downgraded shares of Clorox from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, February 4th. JPMorgan Chase & Co. increased their price target on shares of Clorox from $114.00 to $117.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. TD Cowen lifted their price target on Clorox from $108.00 to $111.00 and gave the stock a “hold” rating in a research report on Wednesday, February 4th. Finally, Jefferies Financial Group decreased their price objective on Clorox from $152.00 to $151.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. One equities research analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $118.73.

Clorox Stock Performance

NYSE:CLX opened at $123.51 on Friday. The company has a market cap of $14.93 billion, a price-to-earnings ratio of 20.18, a PEG ratio of 0.61 and a beta of 0.59. Clorox has a 1 year low of $96.66 and a 1 year high of $159.04. The stock’s 50 day simple moving average is $109.75 and its two-hundred day simple moving average is $113.59. The company has a debt-to-equity ratio of 71.03, a current ratio of 0.74 and a quick ratio of 0.48.

Institutional Trading of Clorox

Several institutional investors have recently added to or reduced their stakes in CLX. Nomura Asset Management Co. Ltd. boosted its holdings in shares of Clorox by 9.0% in the second quarter. Nomura Asset Management Co. Ltd. now owns 335,514 shares of the company’s stock valued at $40,285,000 after purchasing an additional 27,639 shares during the period. Hudson Bay Capital Management LP bought a new stake in Clorox during the 2nd quarter valued at $8,568,000. Vise Technologies Inc. bought a new stake in Clorox during the 2nd quarter valued at $328,000. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Clorox by 64.2% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 25,732 shares of the company’s stock worth $3,173,000 after buying an additional 10,065 shares during the period. Finally, ProShare Advisors LLC grew its position in shares of Clorox by 11.7% during the 3rd quarter. ProShare Advisors LLC now owns 1,297,016 shares of the company’s stock worth $159,922,000 after buying an additional 136,135 shares in the last quarter. Institutional investors own 78.53% of the company’s stock.

More Clorox News

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Zacks raised its FY2028 EPS view to $7.23 and upgraded select quarterly/annual estimates (including Q1 2028 to $1.37 and Q4 2026/2027 increases), signaling modestly better forward earnings visibility that can support the stock.
• Positive Sentiment: Clorox published a consumer research report “Home Care Redefined” that underscores evolving demand for wellness- and convenience-oriented home-care products — a strategic tailwind for branded consumer staples. Home Care Redefined
• Neutral Sentiment: Management presented at the Consumer Analyst Group of New York (CAGNY) conference; slides and prepared remarks provide more detail on strategy, cost actions and growth initiatives — useful for longer-term positioning but not an immediate earnings surprise. CAGNY Slides Transcript
• Negative Sentiment: Zacks trimmed multiple near-term quarterly EPS forecasts (several Q2–Q3 2026/2027 cuts and FY2027 lowered to $6.74), reflecting caution about near-term volume/mix or cost pressure — a potential headwind for sentiment and short-term guidance expectations.
• Negative Sentiment: Wells Fargo issued a “Hold” on CLX (reported as “receives a Hold”), which keeps sell-side sentiment neutral-to-cautious and may limit near-term upside from upgrades. Wells Fargo Hold

About Clorox

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.